MBX Biosciences Advances Hypoparathyroidism Treatment to Phase 3

Once-weekly canvuparatide for hypoparathyroidism met its Phase 2 goal. 63% of patients achieved stable calcium and cut daily supplements. It was well tolerated and is advancing to Phase 3.